Search clinical trials for: RF-CWC

Total 1782 results

M.D. Anderson Cancer Center
Pfizer

Recruiting

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Multiple Myeloma | Post-transplant MRD-guided Maintenance Therapy | Pre-transplant Purging

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Refractory Multiple Myeloma | Recurrent Multiple Myeloma
Emory University
National Cancer Institute (NCI); GlaxoSmithKline

Recruiting

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Plasma Cell Myeloma

United States
John Reneau

Recruiting

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Adult T-Cell Leukemia/Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Multiple Myeloma-Light Chain Only

United States
M.D. Anderson Cancer Center

Active, not recruiting

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Diffuse Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

Recurrent Neuroblastoma | Refractory Neuroblastoma | Recurrent Ganglioneuroblastoma | Refractory Ganglioneuroblastoma
Mayo Clinic

Recruiting

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Recurrent Multiple Myeloma

United States
Mayo Clinic

Recruiting

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Recurrent Indolent Adult Non-Hodgkin Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell Myeloma | Plasmacytoma | Plasma Cell Leukemia

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia | Cutaneous B-cell Non-Hodgkin Lymphoma | Intraocular Lymphoma | Small Intestine Lymphoma | Testicular Lymphoma | B-cell... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Mycosis Fungoides | Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8 | Recurrent Mycosis Fungoides... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Lymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditions

United States
University of Washington
Genzyme, a Sanofi Company

Active, not recruiting

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
University of Arkansas
Amgen

Terminated

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Multiple Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Lymphoma | Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Lymphocytic Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Hematopoietic and Lymphoid Cell Neoplasm

United States
Celgene

Completed

A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677

Healthy Volunteer

United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma

United States, Puerto Rico
National Cancer Institute (NCI)

Not yet recruiting

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVB Prostate Cancer AJCC v8 | Metastatic Breast Carcinoma | Metastatic Prostate Adenocarcinoma
National Cancer Institute (NCI)

Completed

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Chronic Myelomonocytic Leukemia-2

United States
Children's Oncology Group
National Cancer Institute (NCI); University College, London; Medical Research...

Completed

Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma (EURAMOS-1)

Metastatic Osteosarcoma | Localized Osteosarcoma

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

B Acute Lymphoblastic Leukemia | Central Nervous System Leukemia | Testicular Leukemia | B Lymphoblastic Lymphoma | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, New Zealand, Australia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Acute Lymphoblastic Leukemia in Remission

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | B Lymphoblastic Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy | Acute Myeloid Leukemia, Myelodysplasia-Related

United States, Canada, Puerto Rico
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States

Search clinical trials for: RF-CWC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations